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The Editorial on the Research Topic
Advances in Aspergillus fumigatus Pathobiology
Aspergillus fumigatus and other Aspergillus spp. are ubiquitous in our environment. However, their
potential to cause severe disease in humans was ignored for many centuries. The first reported case
of presumed human aspergillosis is from 1791 during the French revolution. A 22-year old soldier
sought medical attention for painful cheek swelling because of a fungus ball of the maxillary sinus
invading the mouth and orbit (Plaignaud, 1791). The patient ultimately recovered after surgery. A
few decades earlier, in 1729, the Italian priest and botanist Pier Antonio Micheli provided the first
description of the fungal genus that he named “Aspergillus” because of the similarity of the conidial
head and spores to the aspergillum, the liturgical implement used to sprinkle holy water in the
Catholic church (Micheli, 1729). During the first half of the twentieth century, Aspergillus spp. were
considered common laboratory contaminants and only an occasional cause of human diseases with
some case reports of chronic bronchopulmonary aspergillosis among farmers, cerebral abscesses,
meningitis, and bone infections (Cawley, 1947). The introduction of steroid therapy in the 1950s,
the later development of anti-neoplastic chemotherapy, and the first hematopoietic stem cell
transplantations during the following decades revealed the devastating potential of these fungi in
patients with severely depressed immune systems.
Invasive aspergillosis (IA) has now emerged as a major infectious threat and the prevalence
and spectrum of the disease has progressed in parallel with advances in medicine and the advent
of new therapies with potent immunosuppressive effects. The cumulative 12-month incidence of
IA is estimated at 1.6% in hematopoietic stem cell transplant recipients and 0.7% in solid organ
transplant recipients, with an overall 1-year mortality of 40–75% (Kontoyiannis et al., 2010; Pappas
et al., 2010). Moreover, IA is increasingly reported in populations with other underlying conditions,
such as intensive-care unit patients, or patients with autoimmune or chronic bronchopulmonary
diseases (Meersseman et al., 2004; Garbino et al., 2011).
Despite a slight improvement in survival rates (Steinbach et al., 2012), the mortality of IA
remains high, and little significant progress has been made in the management of the disease
over the last several decades. Amphotericin B was historically the pillar of antifungal therapy, but
included an unacceptably high rate of failure due to toxicity. At the beginning of this century,
voriconazole demonstrated a better efficacy and safety profile and became the preferred first-line
therapy of IA (Herbrecht et al., 2002). However, emergence of resistance to triazoles as a probable
consequence of the widespread use of fungicides in the agriculture and industry (Vermeulen et al.,
2013) has led to the need for second-line antifungal agents. Echinocandins, such as caspofungin or
micafungin, are now considered as salvage therapy of IA (Maertens et al., 2004), but their lack of
fungicidal activity limits their efficacy. Posaconazole is active againstmostAspergillus spp. However,
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the most frequent mechanism of voriconazole resistance (i.e.,
mutations of the Cyp51A gene) often confers pan-azole
resistance and the increasing use of posaconazole prophylaxis
in patients with hematologic malignancies raises concern about
breakthrough infections due to resistant Aspergillus spp. or other
fungi (Auberger et al., 2012). Combination antifungal therapy,
such as the association of triazoles and echinocandins, has led to
inconclusive results (Marr et al., 2015).
Considerable effort from the research community is dedicated
to the discovery of new antifungal targets. An effective antifungal
agent must be fungal-specific to avoid unacceptable human
toxicity, but this is difficult to achieve as both fungi and humans
are eukaryotes. Indeed, all currently approved antifungal drugs
target the specific components of the fungal cell membrane
(ergosterol) or cell wall (β-1,3-D-glucan). A better understanding
of the molecular pathways involved in fungal metabolism,
virulence, stress response, and resistance are therefore important
steps toward the discovery of novel therapeutic approaches.
The purpose of this research topic is to provide an overview
on the current state of research and to strengthen the links
within the Aspergillus community. Scientists purposefully chosen
from various countries and continents have contributed to this
special issue dealing with all the medical aspects of IA, including
taxonomy, genetics, epidemiology, pathogenesis, antifungal
resistance, and novel therapeutic perspectives. Multiple species
have now been identified within the Aspergillus section
Fumigati and the possible relationship between their metabolite
profiles and pathogenicity are discussed (Frisvad and Larsen).
The worldwide problem of emerging azole resistance among
Aspergillus spp. is illustrated by an interesting epidemiological
study and update of the situation in Asia (Chowdhary et al.).
In addition, the existence of mechanisms of azole resistance
other than mutations of the Cyp51A gene, such as increased
expression of ATP-binding cassette (ABC) transporters, is
highlighted (Moye-Rowley). To counteract emerging resistance,
novel potential antifungal targets are being investigated and
several research groups present their latest updates on the cell
wall integrity signaling pathway (Valiante et al.), the Ras pathway
(Al Abdallah and Fortwendel), the Hsp90-calcineurin network
(Juvvadi et al.; Lamoth et al.), and the regulation of zinc and iron
homeostasis (Schafferer et al.; Vicentefranqueira et al.). Finally,
because innate and adaptive immunity are key determinants in
the development of IA, the analysis of host-pathogen interactions
represents a promising research area. The current knowledge
about the immune responses mediated via T-helper cells is
presented in two reviews (Amarsaikhan and Templeton; Thakur
et al.). The recent identification of host genetic determinants of
IA, such as TLRs polymorphisms, also opens perspectives for
preventive strategies (Oliveira-Coelho et al.).
This overview on the recent advances in A. fumigatus
pathobiology suggests that we are entering a new era in the
approach and management of IA. The epidemiology and
pathophysiology of the disease has become more complex,
with emerging resistance to triazoles and the increased
diversity of immunosuppression types and host susceptibilities.
Combination therapies of existing compounds or novel
molecules that may enhance their activity or modulate the
pattern of host immune recognition, as well as personalized
diagnostic and therapeutic strategies based on individual
susceptibility profiles of high risk patients, may change our
conventional approach of IA and hopefully result in better
outcomes.
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